The drugmaker said the recall of cefdinir for oral suspension was due to a report of a metal piece found in the product bottle.
The FDA has classified the recall as a Class 2, which is issued when the use or exposure to the drug may cause adverse events.
Cefdinir for oral suspension is manufactured by Lupin’s manufacturing facility in central India. The affected lot is F802335 and is packaged in 60-milliliter bottles.
More articles on pharmacy:
Sanofi poaches exec from Novartis
Eli Lilly’s migraine drug 1st approved to reduce cluster headaches: 4 notes
EpiPen shortage will drag on: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
